Product Images Dalfampridine

This appears to be a table showing the results of a clinical trial for Dalfampridine Extended Release Tablets at a 10mg dose taken twice a day by 224 patients compared against a placebo. The results show the percentage increase in walking speed compared to baseline at different intervals (10%, 20%, 30%, 50%, 60%, and over 60%). The table also includes a statistical significance level of p-0.001.*

This is a statistical table with information about patients and their walking speed. There are three groups of patients: one who received a placebo treatment (N=118), one who received a 10mg bid Dllamride Extended eleasTaiet treatment (N=119), and one whose results are not mentioned. The table shows the percent increase in walking speed from baseline for each of the groups, ranging from 20% to 260%. There are also statistical significance values (p<0001 and 0.0333) mentioned.*

Each tablet contains 10 mg of dalfampridine and it should only be taken whole. Tablets should not be divided, crushed, chewed, or dissolved. The usual dosage should be read in the package insert. Store at 25°C with excursions permitted to 15-30°C. Dispense in containers with a child-resistant closure and keep out of reach of children. A medication guide should be provided to each patient. The tablets are manufactured for Micro Labs USA, Inc. and have a GTIN of 00342571275600. The serial number is XXIHKIRRXIKHHKK and the expiration date is YYYY-MM-DD. There is no additional readable information available.*